Literature DB >> 31259557

Enabling Synthesis of ABBV-2222, A CFTR Corrector for the Treatment of Cystic Fibrosis.

Stephen N Greszler1, Bhadra Shelat1, Eric A Voight1.   

Abstract

An enabling preclinical synthetic route to cystic fibrosis candidate ABBV-2222 is described. Two stereoselective steps provide access to an aminochroman intermediate with excellent control, and a late-stage demethylation/difluoromethylation sequence provides efficient access to the target molecule.

Entities:  

Year:  2019        PMID： 31259557     DOI： 10.1021/acs.orglett.9b02099

Source DB:  PubMed          Journal:  Org Lett        ISSN： 1523-7052            Impact factor:   6.005


  3 in total

1.  Fueling the Pipeline via Innovations in Organic Synthesis.

Authors:  Eric A Voight; Stephen N Greszler; Philip R Kym
Journal:  ACS Med Chem Lett       Date:  2021-08-27       Impact factor: 4.632

2.  Discussion Addendum for: Preparation of (S)-tert-ButylPyOx and Palladium-Catalyzed Asymmetric Conjugate Addition of Arylboronic Acids.

Authors:  Stephen R Sardini; Brian M Stoltz
Journal:  Organic Synth       Date:  2021

Review 3.  Recent advances in palladium-catalysed asymmetric 1,4-additions of arylboronic acids to conjugated enones and chromones.

Authors:  Jan Bartáček; Jan Svoboda; Martin Kocúrik; Jaroslav Pochobradský; Alexander Čegan; Miloš Sedlák; Jiří Váňa
Journal:  Beilstein J Org Chem       Date:  2021-05-10       Impact factor: 2.883
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.